Hypereosinophilic syndrome with organ involvement
Eosinophilic · Allergy / Immunology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Persistent marked eosinophilia (typically greater than 1.5 x 10^9/L) causing eosinophil-mediated organ damage - cardiac (endomyocardial fibrosis), neurological, pulmonary, skin or GI - which can be rapidly life-threatening.
Red flags
- Cardiac involvement (heart failure, thrombus, arrhythmia)
- Thromboembolism
- Neurological deficits
- Very high or rapidly rising eosinophil count
Assessment
Differential diagnosis
- Eosinophilic granulomatosis with polyangiitis
- Parasitic infection
- Drug reaction (DRESS)
- Eosinophilic leukaemia
- Lymphoma / secondary eosinophilia
Investigations
- FBC and blood film (eosinophilia)
- Troponin, ECG, echocardiography (cardiac involvement)
- U&E, LFTs
- Investigations for cause (tryptase, FIP1L1-PDGFRA, parasites, imaging)
- Bone marrow if primary/clonal disease suspected
Management
- Assess and support organ function, especially cardiac (a major cause of death)
- Exclude secondary causes (parasites, drugs, malignancy)
- Give high-dose corticosteroids promptly for organ-threatening disease (after excluding untreated strongyloides where relevant)
- Add specific therapy for clonal disease (e.g. imatinib for FIP1L1-PDGFRA-positive disease) on specialist advice
- Anticoagulate for eosinophilic cardiac thrombus per specialist input
- Involve haematology/immunology urgently
Drugs & doses
High-dose corticosteroids for organ-threatening disease
Imatinib for FIP1L1-PDGFRA-positive (myeloid) variant
Anticoagulation for cardiac/intracardiac thrombus per specialist
Consider empirical anti-helminthic (e.g. ivermectin) before steroids if strongyloides risk
Disposition
Admit; ICU/cardiology for cardiac involvement; haematology/immunology involvement.
Complications & pitfalls
- Endomyocardial fibrosis and heart failure
- Thromboembolic events (including stroke)
- Respiratory failure
- Death
Exam pearls
- Cardiac involvement is the leading cause of morbidity and mortality - image the heart early
- Exclude and treat strongyloides before giving steroids where there is exposure risk (steroids can precipitate hyperinfection)
- Identify the FIP1L1-PDGFRA fusion - it responds dramatically to imatinib
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.